Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 3 | 2025 | 208 | 0.910 |
Why?
|
| Liver Neoplasms | 3 | 2025 | 341 | 0.840 |
Why?
|
| Hepatectomy | 1 | 2020 | 25 | 0.670 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 124 | 0.620 |
Why?
|
| Liver Transplantation | 1 | 2020 | 171 | 0.570 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2018 | 2 | 0.560 |
Why?
|
| Crohn Disease | 1 | 2018 | 115 | 0.500 |
Why?
|
| Immunohistochemistry | 3 | 2024 | 977 | 0.240 |
Why?
|
| Metallothionein | 1 | 2024 | 10 | 0.220 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2024 | 6 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 257 | 0.200 |
Why?
|
| Oncolytic Virotherapy | 1 | 2022 | 19 | 0.190 |
Why?
|
| Rare Diseases | 1 | 2021 | 47 | 0.170 |
Why?
|
| Keratin-19 | 1 | 2020 | 2 | 0.170 |
Why?
|
| Stem Cell Niche | 1 | 2020 | 11 | 0.170 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 13 | 0.170 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2021 | 80 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 122 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 168 | 0.160 |
Why?
|
| Epithelial Cells | 1 | 2020 | 217 | 0.150 |
Why?
|
| Transcription Factors | 1 | 2021 | 570 | 0.140 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 26 | 0.130 |
Why?
|
| Adult | 3 | 2024 | 14205 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 615 | 0.110 |
Why?
|
| Time Factors | 1 | 2020 | 2987 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 206 | 0.100 |
Why?
|
| Humans | 8 | 2025 | 52441 | 0.100 |
Why?
|
| Male | 4 | 2024 | 26874 | 0.100 |
Why?
|
| Middle Aged | 3 | 2024 | 13133 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1429 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5508 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 1483 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2020 | 6694 | 0.070 |
Why?
|
| Aged | 1 | 2020 | 10242 | 0.060 |
Why?
|
| Female | 3 | 2024 | 28277 | 0.060 |
Why?
|
| CTLA-4 Antigen | 1 | 2025 | 32 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 46 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 86 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 140 | 0.060 |
Why?
|
| Mice | 2 | 2025 | 5899 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2025 | 251 | 0.050 |
Why?
|
| Vesiculovirus | 1 | 2022 | 6 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 871 | 0.050 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 18 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 58 | 0.040 |
Why?
|
| Pedigree | 1 | 2021 | 126 | 0.040 |
Why?
|
| Vimentin | 1 | 2020 | 31 | 0.040 |
Why?
|
| Arteries | 1 | 2021 | 93 | 0.040 |
Why?
|
| Biliary Tract | 1 | 2020 | 13 | 0.040 |
Why?
|
| Child | 2 | 2024 | 7194 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 1888 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 56 | 0.040 |
Why?
|
| Animals | 2 | 2025 | 13485 | 0.040 |
Why?
|
| Keratin-7 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Gastric Fundus | 1 | 2017 | 6 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2017 | 7 | 0.030 |
Why?
|
| Cardia | 1 | 2017 | 10 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2017 | 21 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 70 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2024 | 4046 | 0.030 |
Why?
|
| Cisplatin | 1 | 2017 | 282 | 0.030 |
Why?
|
| Young Adult | 1 | 2024 | 4346 | 0.030 |
Why?
|
| Liver | 1 | 2020 | 1150 | 0.030 |
Why?
|
| Adolescent | 1 | 2024 | 6713 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1020 | 0.020 |
Why?
|